胰腺癌中肿瘤标志物CA 242与CA 19-9及癌胚抗原（CEA）的比较。

Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.

作者信息

Ozkan Hasan, Kaya Muhsin, Cengiz Abdulkadir

机构信息

Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.

出版信息

Hepatogastroenterology. 2003 Sep-Oct;50(53):1669-74.

PMID:14571813

Abstract

BACKGROUND/AIMS: Although there are a variety of tumor markers used for diagnosis of pancreatic carcinoma, the sensitivity and specificity of those markers have not yet reached an ideal level. The aim of this study was to compare the diagnostic value of CA 242 with CA 19-9 and CEA in the patients with pancreatic cancer.

METHODOLOGY

Serum CA 242, CA 19-9 and CEA levels were determined in 135 subjects in the following groups: Pancreatic cancer (n = 40), cholangiocellular carcinoma (n = 15), hepatocellular carcinoma (n = 10), cirrhosis (n = 7), chronic active hepatitis (n = 7), choledochal stone (n = 12), chronic pancreatitis (n = 9), acute pancreatitis (n = 6), and healthy controls (n = 29).

RESULTS

An elevated serum CA 242 concentration (> 20 U/mL) was found in 30 out of 40 (70%) (mean; 2163 +/- 838 U/mL) patients with pancreas cancer, in 11 out of 15 patients with cholangiocellular carcinoma (93.3%) (mean 916 +/- 529 U/mL), in none of patients with hepatocellular carcinoma and healthy controls. Slightly elevated CA 242 concentration was found in 6 out of 41 patients with benign hepatobiliary and pancreatic disease (range 0.4-97.8 U/mL) (1 acute pancreatitis, 2 chronic pancreatitis, 1 cirrhosis, 2 choledochal stone). Mean serum CA 242, CA 19-9 and CEA levels of the pancreas cancer group were significantly higher than those of the other groups except the cholangiocellular carcinoma group. There was no significant difference between the stage of pancreas cancer regarding mean serum CA 242, CA 19-9 and CEA level. There was positive correlation between serum CA 242 and CA 19-9 level. In the pancreas cancer, the sensitivity of CA 242, CA 19-9 and CEA was 75%, 80%, 40%, respectively and the specificity of those markers was 85.5%, 67.5% and 73%, respectively.

CONCLUSIONS

In conclusion, the advantage of CA 242 compared to CA 19-9 is that its specificity is higher than that of CA 19-9 in the diagnosis of pancreas cancer.

摘要

背景/目的：尽管有多种肿瘤标志物用于胰腺癌的诊断，但这些标志物的敏感性和特异性尚未达到理想水平。本研究的目的是比较CA 242与CA 19 - 9和癌胚抗原（CEA）在胰腺癌患者中的诊断价值。

方法

测定了135名受试者的血清CA 242、CA 19 - 9和CEA水平，这些受试者分为以下几组：胰腺癌（n = 40）、胆管细胞癌（n = 15）、肝细胞癌（n = 10）、肝硬化（n = 7）、慢性活动性肝炎（n = 7）、胆总管结石（n = 12）、慢性胰腺炎（n = 9）、急性胰腺炎（n = 6）以及健康对照（n = 29）。

结果

40例胰腺癌患者中有30例（70%）（均值；2163 ± 838 U/mL）血清CA 242浓度升高（> 20 U/mL），15例胆管细胞癌患者中有11例（93.3%）（均值916 ± 529 U/mL）升高，肝细胞癌患者和健康对照中均无升高。41例良性肝胆胰疾病患者中有6例（范围0.4 - 97.8 U/mL）（1例急性胰腺炎、2例慢性胰腺炎、1例肝硬化、2例胆总管结石）CA 242浓度轻度升高。胰腺癌组的血清CA 242、CA 19 - 9和CEA均值显著高于除胆管细胞癌组外的其他组。胰腺癌分期在血清CA 242、CA 19 - 9和CEA水平方面无显著差异。血清CA 242与CA 19 - 9水平呈正相关。在胰腺癌中，CA 242、CA 19 - 9和CEA的敏感性分别为75%、80%、40%，这些标志物的特异性分别为85.5%、67.5%和73%。